Skip to main content

Ventricular assist devices (VADs) are transforming the treatment of patients with advanced heart failure

 

In fact, few advancements in healthcare today have a greater potential to impact heart failure than VADs.

Patients with advanced heart failure experience an impaired quality of life and the significant personal and economic impact of recurrent hospitalizations. A substantial number of patients who could benefit from this therapy are not currently being referred or considered for VAD therapy.1

When managing patients with advanced heart failure, consider discussing referral for VAD therapy while they still have time to make a choice.

If your patient is persistently symptomatic and has one or more of the C.H.O.I.C.E. risk factors, he or she may be a candidate for VAD Therapy.

C

CLASS IIIB / IV

NYHA classification symptoms with an ejection fraction (EF) <30%2

H

HOSPITALIZATION

Each subsequent hospitalization for heart failure is associated with a significant further reduction in survival1

O

OPTIMAL

Medical management not effective2,3

I

INOTROPE

Therapy being considered or initiated3

C

CLINICAL

Parameters worsening4

E

EVOLVING

Or progressing organ dysfunction2,3

VADS ADDRESS A NEED

Heart failure is a serious disease that affects an estimated 26 million patients worldwide and is the leading cause of hospitalization in the U.S. and Europe.7 Worldwide 50,000 candidates are waiting for heart transplantation,1,2 yet only approximately 4,000 heart transplants are performed each year.8

VADS ARE GLOBALLY ENDORSED

51% of heart transplant patients worlwide are bridge-to-transplant with a VAD.

VAD therapy has been globally endorsed as an option by the:

  • American Heart Association (AHA)2
  • European Society of Cardiology (ESC)3
  • International Society for Heart and Lung Transplantation (ISHLT)9

Changing the way heart failure is treated
Download Brochure


References

1. Miller, L, et al. Is left ventricular assist device therapy underutilized in the treatment of heart failure? Circulation. 2011;123:1552-1558.
2. Peura, J, et al. AHA. Recommendations for the use of mechanical circulatory support: device strategies and patient selection.2012;126:2653-2667.
3. Ponikowski, P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 2012. Eur Heart J. 2016;37:2129–2200.
4. Thorvaldsen, T, et al. Triage of patients with moderate to severe heart failure who should be referred to a heart failure center. J Am Coll Cardiol. 2014;63:661-671.
5. Daubert, J, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: Implant and follow-up recommendations and management. Europace. 2012;14:1236-1286.
6. Banner, N, et al. UK Guidelines for referral and assessment of adults for heart transplantation. Heart. 2011;97:1520-1527.
7. Ambrosy, P, et al. The global health and economic burden of hospitalizations for heart failure. Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123 -1133.
8. Lund, LH et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. JHLT.2016 Oct, 35(10): 1149-1205.
9. Feldman, D, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: Executive Summary. J Heart Lung Transplant 2013;32:157–187.